Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Research & Development (2020 - 2025)

Maxcyte (MXCT) has disclosed Research & Development for 6 consecutive years, with $5.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development changed 0.0% to $5.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $22.1 million, a 5.77% decrease, with the full-year FY2024 number at $22.2 million, down 6.68% from a year prior.
  • Research & Development was $5.3 million for Q3 2025 at Maxcyte, down from $6.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $6.7 million in Q1 2024 to a low of $2.7 million in Q3 2021.
  • A 5-year average of $5.2 million and a median of $5.6 million in 2024 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: crashed 39.2% in 2021, then soared 93.86% in 2022.
  • Maxcyte's Research & Development stood at $3.3 million in 2021, then surged by 71.01% to $5.7 million in 2022, then grew by 2.0% to $5.8 million in 2023, then fell by 21.02% to $4.6 million in 2024, then increased by 15.21% to $5.3 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Research & Development are $5.3 million (Q3 2025), $6.3 million (Q2 2025), and $5.9 million (Q1 2025).